Elderly patients undergoing transcatheter aortic valve replacement (TAVR) for symptomatic severe aortic stenosis may fare better with the SAPIEN 3 prosthesis than with the ACURATE neo transcatheter heart valve, according to a recent study presented at the 31st Transcatheter Cardiovascular Therapeutics scientific symposium (TCT 2019).
Transitioning from dual antiplatelet therapy (DAPT) to aspirin monotherapy at 3 months following implantation of a thin-strut bioresorbable-polymer stent is safe for patients with high bleeding risk (HBR), according to the results of the EVOLVE Short DAPT trial presented at the 31st Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium.
Standard-dose ticagrelor significantly increased the risk of bleeding events among Korean patients with acute coronary syndrome (ACS) compared with clopidogrel, according to the TICAKOREA* study presented at TCT 2019.
There appears to be little benefit to adding aspirin to ticagrelor in patients with acute coronary syndromes (ACS) who have undergone percutaneous coronary intervention (PCI), with a similar rate of all-cause mortality and new Q-wave myocardial infarction (MI) at 1 year between those who received ticagrelor monotherapy and a ticagrelor-aspirin combo, according to a non-prespecified, post hoc exploratory analysis of the GLOBAL LEADERS* trial.
Treatment with apixaban and a P2Y12 inhibitor, but leaving off aspirin, may be an effective and safe option for patients with atrial fibrillation (AF) and acute coronary syndrome (ACS) regardless of presentation, a new analysis of the AUGUSTUS* trial has shown. However, questions remain on when to drop aspirin in patients with AF, requiring both dual antiplatelet therapy (DAPT) and anticoagulation.
Individuals with left main coronary artery disease (CAD) who underwent percutaneous coronary intervention (PCI) or coronary artery bypass graft (CABG) continued to show similar rates of the primary outcome (composite of death, stroke, or myocardial infarction), highlighting the potential of PCI as a CABG alternative in this patient setting, according to the final results of the EXCEL* trial presented at TCT 2019.
Ticagrelor monotherapy significantly reduces bleeding without increasing the risk of ischaemic events (all-cause death and myocardial infarction (MI)) in high-risk patients who have undergone percutaneous coronary intervention (PCI), according to the TWILIGHT* study presented at TCT 2019.
The combination therapy comprising carfilzomib, cyclophosphamide and dexamethasone (KCd) is effective, with a tolerable safety profile, in an Asian cohort with high-risk multiple myeloma (MM) — thus providing a more economical alternative as a potential upfront regimen in resource-limited settings, according to leading experts during a myeloma education webinar.
Extremes of sleep duration (≤5 or ≥10 hours/day), which is a known mortality risk factor in the general population, may increase absolute mortality in adults with type 2 diabetes (T2D), a prospective study has shown.
Insulin icodec, an in-development basal insulin analogue administered once weekly, was as effective as once-daily insulin glargine in patients with type 2 diabetes (T2D) insufficiently controlled with metformin with or without a DPP-4* inhibitor, according to a phase II trial presented at EASD 2020.